<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00177554</url>
  </required_header>
  <id_info>
    <org_study_id>UPCI #03-005</org_study_id>
    <nct_id>NCT00177554</nct_id>
  </id_info>
  <brief_title>Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma</brief_title>
  <official_title>Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the complete response rate when CHOP-R chemotherapy
      in followed by Zevalin in previous untreated patients with follicular lymphoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with follicular lymphoma who require therapy and have been previously untreated are
      eligible for this non-randomized, phase II study evaluating up front therapy with CHOP-R x 3
      cycles followed by zevalin and 4 additional weeks of rituxan.The complete response will be
      determined by combining IWC criteria and PET scanning.Secondary objectives include PET-CT
      conversion rate, frequency and severity of adverse events, duration of complete remission and
      time to next lymphoma therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>May 2007,May 2008, May2009, May 2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PET-CT conversion rate</measure>
    <time_frame>May2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>May 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete response</measure>
    <time_frame>May 2007,May 2008, May 2009, May 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next lymphoma therapy</measure>
    <time_frame>May 2207,May2008,May2009, May2010</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy and Radioimmunotherapy</intervention_name>
    <description>CHOP-R x 3 cycles followed by zevalin and extended rituximab</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Conformed diagnosis of follicular lymphoma, grades 1,2 or 3

          -  No prior chemotherapy

          -  No prior monoclonal antibody therapy

          -  Bulky or symptomatic disease, stage II-IV

          -  Performance status 0-2

        Exclusion Criteria:

          -  Impaired bone marrow reserve

          -  Presence of CNS lymphoma

          -  Serious nonmalignant disease or active infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel A Jacobs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC Cancer Centers</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>May 27, 2008</last_update_submitted>
  <last_update_submitted_qc>May 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Samuel Jacobs,MD</name_title>
    <organization>University of Pittsburgh cancer Institute</organization>
  </responsible_party>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

